EXEL · Exelixis
459 filings
EXEL SEC Filings
Exelixis - 459 total filings
EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.
- 8-K · Feb 16, 2016
- 10-K · Feb 29, 2016
- 8-K · Feb 29, 2016
- 10-Q · May 4, 2016
- 8-K · May 4, 2016
- 8-K · May 26, 2016
- 10-Q · Aug 3, 2016
- 8-K · Aug 3, 2016
- 8-K · Aug 9, 2016
- 8-K · Aug 22, 2016
- 8-K · Sep 26, 2016
- 10-Q/A · Sep 30, 2016
- 8-K · Nov 3, 2016
- 10-Q · Nov 3, 2016
- 8-K · Nov 22, 2016
- 8-K · Dec 21, 2016
- 8-K · Jan 31, 2017
- 8-K · Feb 27, 2017
- 10-K · Feb 27, 2017
- 10-Q · May 1, 2017
- 8-K · May 1, 2017
- 8-K · May 2, 2017
- 8-K · May 11, 2017
- 8-K · May 25, 2017
- 10-Q/A · Jul 14, 2017
- 8-K · Jul 20, 2017
- 8-K · Aug 2, 2017
- 10-Q · Aug 2, 2017
- 8-K/A · Sep 8, 2017
- 8-K · Sep 8, 2017
- 8-K · Nov 1, 2017
- 10-Q · Nov 1, 2017
- 8-K · Feb 16, 2018
- 10-K · Feb 26, 2018
- 8-K · Feb 26, 2018
- 8-K · Apr 9, 2018
- 8-K · May 2, 2018
- 10-Q · May 2, 2018
- 8-K · May 24, 2018
- 10-Q · Aug 1, 2018
- 8-K · Aug 1, 2018
- 10-Q · Nov 1, 2018
- 8-K · Nov 1, 2018
- 8-K · Feb 12, 2019
- 8-K · Feb 21, 2019
- 10-K · Feb 22, 2019
- 8-K · Mar 5, 2019
- 8-K · Apr 5, 2019
- 8-K · Apr 25, 2019
- 8-K · May 1, 2019
- 10-Q · May 1, 2019
- 8-K · May 23, 2019
- 8-K · Jun 20, 2019
- 10-Q · Jul 31, 2019
- 8-K · Jul 31, 2019
- 8-K · Sep 26, 2019
- 8-K · Oct 7, 2019
- 10-Q · Oct 30, 2019
- 8-K · Oct 30, 2019
- 8-K · Dec 19, 2019
- 8-K · Jan 13, 2020
- 8-K · Feb 20, 2020
- 10-K · Feb 25, 2020
- 8-K · Feb 25, 2020
- 8-K · Mar 2, 2020
- 8-K · Apr 20, 2020
- 8-K · May 5, 2020
- 10-Q · May 5, 2020
- 8-K · May 12, 2020
- 8-K · May 22, 2020
- 8-K · Aug 6, 2020
- 10-Q · Aug 6, 2020
- 8-K · Nov 5, 2020
- 10-Q · Nov 5, 2020
- 8-K · Jan 11, 2021
- 8-K · Feb 5, 2021
- 8-K · Feb 10, 2021
- 10-K · Feb 11, 2021
- 8-K · Mar 3, 2021
- 8-K · Mar 5, 2021
- 10-Q · May 6, 2021
- 8-K · May 6, 2021
- 8-K · May 11, 2021
- 8-K · May 27, 2021
- 8-K · Jun 21, 2021
- 8-K · Jun 21, 2021
- 8-K · Aug 5, 2021
- 10-Q · Aug 5, 2021
- 8-K · Nov 2, 2021
- 10-Q · Nov 2, 2021
- 8-K · Dec 17, 2021
- 8-K · Jan 10, 2022
- 8-K · Feb 17, 2022
- 10-K · Feb 18, 2022
- 8-K · Feb 23, 2022
- 8-K · Apr 13, 2022
- 10-Q · May 10, 2022
- 8-K · May 10, 2022
- 8-K · May 27, 2022
- 8-K · Jul 19, 2022
- 8-K · Aug 9, 2022
- 10-Q · Aug 9, 2022
- 8-K · Sep 2, 2022
- 10-Q · Nov 1, 2022
- 8-K · Nov 1, 2022
- 8-K · Dec 15, 2022
- 8-K · Jan 9, 2023
- 10-K · Feb 7, 2023
- 8-K · Feb 7, 2023
- 8-K · Mar 20, 2023
- 8-K · Mar 22, 2023
- 8-K · Apr 13, 2023
- 8-K · May 8, 2023
- 10-Q · May 9, 2023
- 8-K · May 9, 2023
- 8-K · Jun 5, 2023
- 8-K · Jul 24, 2023
- 8-K · Aug 1, 2023
- 10-Q · Aug 1, 2023
- 8-K · Aug 23, 2023
- 8-K · Sep 19, 2023
- 10-Q · Nov 1, 2023
- 8-K · Nov 1, 2023
- 8-K · Dec 20, 2023
- 8-K · Jan 8, 2024
- 10-K · Feb 6, 2024
- 8-K · Feb 6, 2024
- 8-K · Mar 29, 2024
- 8-K · Apr 30, 2024
- 10-Q · Apr 30, 2024
- 8-K · May 10, 2024
- 8-K · May 20, 2024
- 8-K · Jun 3, 2024
- 8-K · Aug 6, 2024
- 10-Q · Aug 6, 2024
- 8-K · Oct 15, 2024
- 8-K · Oct 15, 2024
- 10-Q · Oct 29, 2024
- 8-K · Oct 29, 2024
- 8-K · Jan 13, 2025
- 8-K · Feb 11, 2025
- 10-K · Feb 11, 2025
- 8-K · Feb 21, 2025
- 8-K · Mar 31, 2025
- 10-Q · May 13, 2025
- 8-K · May 13, 2025
- 8-K · Jun 2, 2025
- 8-K · Jul 28, 2025
- 10-Q · Jul 28, 2025
- 8-K · Aug 29, 2025
- 10-Q · Nov 4, 2025
- 8-K · Nov 4, 2025
- 8-K · Nov 7, 2025
- 8-K · Jan 12, 2026
- 8-K · Feb 10, 2026
- 10-K · Feb 10, 2026
- 10-Q · May 5, 2026
- 8-K · May 5, 2026
- 8-K · May 29, 2026
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026
- 8-K · Aug 31, 2026
- 8-K · Sep 11, 2026
- 8-K · Oct 29, 2026
- 10-Q · Oct 29, 2026
Exelixis Quarterly Report for Q3 Ended Oct 2, 2026
Exelixis, Inc. reported net product revenues of $604.9 million for the third quarter of 2026, up from $542.9 million a year earlier, and total revenues of $658.7 million versus $597.8 million. Net income was $218.1 million, or $0.85 per diluted share, compared with $193.6 million, or $0.69 per diluted share, in the prior-year quarter. Growth was driven mainly by CABOMETYX, with the company citing a 6% increase in units sold and a 5% increase in average net selling price, while research and development ($209.5 million) and selling, general and administrative ($154.6 million) expenses rose as the company prepared for zanzalintinib's anticipated launch. The company ended the period with $1.4 billion in cash, cash equivalents and marketable securities, down from $1.7 billion at December 31, 2025, largely due to $1.0 billion of share repurchases in the first nine months. Operating cash flow was $839.5 million for the nine months, and management states it expects current resources to fund operations for at least 12 months. Under the May 2026 repurchase program, $347.9 million remained available as of September 30, 2026. Key pipeline and legal developments include the FDA extending the review of the zanzalintinib NDA (with atezolizumab for metastatic colorectal cancer) to a PDUFA date of March 3, 2027, and the Federal Circuit affirming the validity of several CABOMETYX patents against MSN, with a separate trial scheduled for November 2026. The FDA also granted full approval to Handa's 505(b)(2) NDA for a cabozantinib product on September 3, 2026, and the company entered a settlement and license agreement with Azurity on October 28, 2026.
Exelixis 8-K Report, Financial Results (Oct 29, 2026)
Exelixis, Inc. (Nasdaq: EXEL) reported third-quarter 2026 financial results on October 29, 2026, furnishing a press release as Exhibit 99.1. Total revenues were $658.7 million, up from $597.8 million a year earlier, driven by net product revenues of $604.9 million (compared with $542.9 million), which the company attributed to higher sales volume and a higher average net selling price. Collaboration revenues were $53.8 million, versus $54.8 million. GAAP net income was $218.1 million, or $0.85 per diluted share, compared with $193.6 million, or $0.69 per diluted share, a year earlier. Non-GAAP diluted EPS, which excludes stock-based compensation net of tax, was $0.94. Research and development expenses rose to $209.5 million and selling, general and administrative expenses rose to $154.6 million. The company updated its 2026 guidance, lowering the expected effective tax rate to 16% to 18% from 21% to 23%, while raising cost of goods sold to approximately 4% of net product revenues from 3.5% to 4.5%. Total revenue guidance ($2.500 billion to $2.550 billion) and net product revenue guidance ($2.300 billion to $2.350 billion) were unchanged and do not reflect any potential zanzalintinib launch. The FDA is reviewing the zanzalintinib NDA for previously treated metastatic colorectal cancer in combination with atezolizumab, with a PDUFA target action date of March 3, 2027 after a three-month extension. The company also disclosed a $750 million stock repurchase authorization from May 2026, under which it had bought back $402.1 million at an average price of $54.03 per share by quarter end. The filing also reports a settlement and license agreement with Azurity Pharmaceuticals, entered October 28, 2026, granting a license beginning December 1, 2030, and a Federal Circuit decision in August 2026 upholding patents against MSN Laboratories, which sets an effective date for any MSN ANDA approval of no earlier than January 15, 2030. Topline results from the phase 3 STELLAR-304 trial are expected in the first quarter of 2027.
Exelixis 8-K Report, Corporate Update (Sep 11, 2026)
Exelixis, Inc. filed this Form 8-K to report that on September 10, 2026, the U.S. Food and Drug Administration notified the company that it had extended the review period for its new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer, by three months. The extension followed an FDA information request to which Exelixis responded by submitting updated safety and efficacy data, which the FDA has deemed a major amendment. The revised Prescription Drug User Fee Act (PDUFA) action date is now March 3, 2027. The filing does not state the original action date, the specific content of the updated data, or the outcome of the review. Investors should note that the timeline for a potential approval decision on this indication has been pushed back by three months. The filing is a brief Item 8.01 (Other Events) disclosure signed by Brenda J. Hefti, Senior Vice President and General Counsel, on September 11, 2026.
Exelixis 8-K Report, Corporate Update (Aug 31, 2026)
Exelixis announced that the U.S. Court of Appeals for the Federal Circuit affirmed the District of Delaware's judgment in Exelixis, Inc. v. MSN Laboratories Private Limited et al. (Appeal No. 25-1236) that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid. The Court of Appeals also dismissed as moot MSN's appeal regarding the validity of U.S. Patent No. 11,298,349, which expires on February 10, 2032, and vacated the portion of the district court's decision addressing that patent. Based on the appellate opinion, the effective date of any final FDA approval of MSN's ANDA will not be earlier than January 15, 2030, the expiration date of the three upheld patents. The filing states this is subject to further appellate proceedings, applicable regulatory exclusivity, and the outcome of separate litigation over U.S. Patent No. 12,128,039, which expires in February 2032. Trial in that litigation is currently scheduled to begin in November 2026. The filing is a Form 8-K under Item 8.01 (Other Events) and includes forward-looking statements about the timing of any MSN generic launch in the U.S., pending litigation outcomes, and regulatory exclusivity, which the company notes are subject to the risks described in its Form 10-K and Form 10-Q filings.
Exelixis Quarterly Report for Q2 Ended Jul 3, 2026
Exelixis, Inc. reported strong second-quarter 2026 results, with total revenues of $628.7 million, up from $568.3 million in the second quarter of 2025, and net income of $212.1 million, or $0.82 per diluted share, compared with $184.8 million, or $0.65 per diluted share, a year earlier. Net product revenues were $573.0 million, driven by CABOMETYX, which generated $570.6 million in the quarter. Research and development expenses were $212.0 million and selling, general and administrative expenses were $147.6 million, with SG&A rising in part on pre-launch marketing for zanzalintinib. Cash, cash equivalents and marketable securities totaled $1.38 billion at June 30, 2026, down from $1.66 billion at December 31, 2025, as the company returned capital through stock repurchases. Repurchases under the two stock repurchase programs totaled $902.2 million through June 30, 2026, with about $597.8 million remaining under the May 2026 program. Management states that current cash and cash equivalents and marketable securities, together with product and collaboration revenues, will fund operations for at least 12 months. The filing highlights ongoing pipeline and regulatory events. Zanzalintinib, in combination with atezolizumab, is under FDA review for previously treated metastatic colorectal cancer with a PDUFA target action date of December 3, 2026. The STELLAR-303 final overall survival analysis in the non-liver metastases subpopulation was not statistically significant. The company also disclosed multiple Paragraph IV patent challenges to CABOMETYX from generic and 505(b)(2) filers, and the filing notes that the sale of competing cabozantinib products before patent expiration could materially harm the business.
Exelixis 8-K Report, Financial Results (Aug 5, 2026)
Exelixis, Inc. reported financial results for the second quarter ended June 30, 2026 (the filing's fiscal quarter ended July 3, 2026) in a press release furnished as Exhibit 99.1 to this Form 8-K. Total revenues were $628.7 million, up from $568.3 million a year earlier, driven by net product revenues of $573.0 million (versus $520.0 million), which the company attributed primarily to higher sales volume. GAAP net income was $212.1 million, or $0.82 per diluted share, compared with $184.8 million, or $0.65 per diluted share, in the prior-year quarter. Non-GAAP net income was $237.1 million, or $0.91 per diluted share. Research and development expenses rose to $212.0 million and SG&A expenses rose to $147.6 million. Exelixis lowered its FY 2026 guidance. Total revenues are now expected at $2.500 billion to $2.550 billion (previously $2.525 billion to $2.625 billion), net product revenues at $2.300 billion to $2.350 billion (previously $2.325 billion to $2.425 billion), and R&D expenses at $825 million to $875 million (previously $875 million to $925 million). Guidance excludes any revenue from a potential launch of zanzalintinib in metastatic colorectal cancer. The FDA is reviewing the zanzalintinib NDA, with a PDUFA target action date of December 3, 2026. The company repurchased $311.6 million of stock in the quarter at an average price of $47.85 per share, completed the $750 million October 2025 repurchase program, and began executing a new $750 million program authorized in May 2026 that runs through December 31, 2027. The filing also outlines pipeline milestones, including topline STELLAR-304 results expected in the second half of 2026 and initiation of the STELLAR-316 pivotal trial in mid-2026.
Exelixis 8-K Report, Executive Changes (May 29, 2026)
Exelixis, Inc. reported results from its 2026 Annual Meeting of Stockholders, held via live webcast on May 26, 2026. At the meeting, stockholders approved the amendment and restatement of the Exelixis, Inc. 2017 Equity Incentive Plan (the 2017 Plan), which became effective immediately upon approval. The filing incorporates by reference the plan summary in "Proposal 3" of the definitive proxy statement filed April 15, 2026, and the full plan text is filed as Exhibit 10.1. Stockholders elected all 11 nominated directors to serve until the 2027 annual meeting. Each nominee received more votes FOR than AGAINST, though the AGAINST votes were notably higher for some nominees, such as Maria C. Freire, Ph.D. (180,367,648 FOR and 26,067,310 AGAINST) and Stelios Papadopoulos, Ph.D. (198,500,120 FOR and 7,922,275 AGAINST). Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending January 1, 2027, with 222,343,120 votes FOR and 6,485,691 AGAINST. Stockholders approved the 2017 Plan with 196,926,657 votes FOR and 9,343,837 AGAINST. On the advisory Say on Pay proposal, stockholders approved the compensation of named executive officers, with 163,104,135 votes FOR and 43,156,553 AGAINST, a higher level of opposition than on the other proposals.
Exelixis Quarterly Report for Q1 Ended Apr 3, 2026
Exelixis, Inc. reported first-quarter 2026 total revenues of $610.8 million, up from $555.4 million in the first quarter of 2025, with net product revenues of $555.0 million versus $513.3 million a year earlier. Net income rose to $210.5 million, or $0.79 per diluted share, compared with $159.6 million, or $0.55 per diluted share, in the prior-year quarter. Growth was driven mainly by CABOMETYX, which generated $552.8 million in net product revenues, and by collaboration revenues of $55.8 million, which included a $7.7 million recognition tied to an $8.0 million Takeda commercial milestone. Research and development expenses declined to $199.9 million from $212.2 million, reflecting lower clinical trial costs, while selling, general and administrative expenses rose to $139.6 million, citing marketing for the anticipated zanzalintinib launch. Capital deployment was significant. Cash, cash equivalents and marketable securities fell to $1.43 billion from $1.66 billion at December 31, 2025, primarily because of $430.4 million in cash paid for share repurchases. The company had repurchased 13.7 million shares for $590.6 million under its October 2025 program, with about $159.4 million remaining, and in May 2026 its Board authorized an additional $750.0 million repurchase program through December 31, 2027. Working capital declined to $837.7 million. Management stated that existing resources should support operations for at least 12 months. The filing highlights pipeline and regulatory events, including FDA acceptance of the zanzalintinib NDA for previously treated metastatic colorectal cancer with a PDUFA target date of December 3, 2026, and the expected final OS analysis of STELLAR-303 in mid-2026. It also discusses generic litigation: MSN, Sun (settled in December 2025), and Azurity are consolidated for trial scheduled November 2, 2026, and a Handa 505(b)(2) application for cabozantinib capsules is under challenge.
Exelixis 8-K Report, Financial Results (May 5, 2026)
Exelixis, Inc. (Nasdaq: EXEL) reported financial results for the first quarter of 2026 (quarter ended April 3, 2026, presented as March 31, 2026) in a press release furnished as Exhibit 99.1 to this Form 8-K filed May 5, 2026. Total revenues were $610.8 million, compared with $555.4 million in the prior-year period, driven by net product revenues of $555.0 million (versus $513.3 million), which the company attributed primarily to higher sales volume. Collaboration revenues were $55.8 million, versus $42.2 million. GAAP net income was $210.5 million, or $0.79 per diluted share, compared with $159.6 million, or $0.55 per diluted share, a year earlier. Non-GAAP net income was $232.8 million, or $0.87 per diluted share. Exelixis maintained its fiscal 2026 guidance, which does not reflect any revenue from a potential U.S. approval and launch of zanzalintinib in previously treated metastatic colorectal cancer. The key regulatory item is the FDA's acceptance of the New Drug Application for zanzalintinib in combination with atezolizumab, under standard review with a PDUFA target action date of December 3, 2026. Pipeline updates include expected topline STELLAR-304 results in the second half of 2026, an expected mid-2026 final analysis of overall survival in patients without liver metastases in STELLAR-303, expected initiation of STELLAR-316 in mid-2026, and the start of Merck's LITESPARK-034 phase 3 trial in April 2026. On capital allocation, Exelixis had repurchased $590.6 million of stock under its October 2025 program at an average price of $43.14 per share as of quarter end, and expected to complete the remaining amount in May 2026. The Board authorized an additional repurchase of up to $750 million of common stock by December 31, 2027.
Exelixis 8-K Report, Financial Results (Feb 10, 2026)
Exelixis, Inc. (Nasdaq: EXEL) reported fourth-quarter and full-year 2025 results in a press release furnished as Exhibit 99.1 to this Item 2.02 Form 8-K, dated February 10, 2026. Total revenues were $598.7 million for the fourth quarter and $2,320.1 million for the fiscal year 2025, versus $566.8 million and $2,168.7 million in the comparable 2024 periods. Net product revenues rose to $546.6 million in the quarter and $2,122.8 million for the year, driven primarily by higher sales volume, while collaboration revenues fell for the year to $197.3 million from $359.3 million, mainly on lower milestone revenues and development cost reimbursements. GAAP diluted EPS was $0.88 for the quarter and $2.78 for the year; non-GAAP diluted EPS, which excludes stock-based compensation, was $0.94 and $3.08, respectively. For 2026, Exelixis is maintaining its prior guidance of $2.525 billion to $2.625 billion in total revenues and $2.325 billion to $2.425 billion in net product revenues. This guidance excludes any revenue from a potential U.S. launch of zanzalintinib in previously treated metastatic colorectal cancer (CRC) when combined with atezolizumab. The FDA accepted the zanzalintinib NDA with a standard review and a PDUFA target action date of December 3, 2026. The company also expects topline STELLAR-303 (overall survival in non-liver metastases patients) and STELLAR-304 data in mid-2026, and plans to start the STELLAR-316 and STELLAR-201 trials in mid-2026. Capital return was active: Exelixis repurchased $264.5 million of stock in the fourth quarter at an average price of $43.17 per share, completed its $500 million program, and began executing a new $750 million authorization that runs through December 31, 2026.
Exelixis Annual Report, Year Ended Jan 2, 2026
Exelixis, Inc. (Exelixis, we, our or us) reported 2025 as its ninth consecutive year of annual profitability, with total revenues of $2,320.1 million, up from $2,168.7 million in 2024, and net income of $782.6 million, or $2.78 per diluted share, compared with $521.3 million, or $1.76 per diluted share, in 2024. Net product revenues rose to $2,122.8 million, driven by CABOMETYX, which generated $2,113.4 million, with the filing citing a 16% increase in CABOMETYX units sold, largely from first-line RCC use with nivolumab and previously treated advanced NET. Collaboration revenues fell to $197.3 million from $359.3 million, reflecting lower license revenue from the absence of the large 2024 Ipsen sales milestone. The company ended 2025 with $1.66 billion in cash, cash equivalents and marketable securities, versus $1.75 billion a year earlier, after returning cash through share repurchases. It repurchased 30.2 million shares for $1,159.7 million under its repurchase programs, and $590.2 million remained available under the October 2025 program, which runs through December 31, 2026. Operating cash flow was $884.3 million. Research and development expense declined to $825.0 million from $910.4 million, while management projects R&D expense may increase in 2026 due to zanzalintinib, XB628, XB371 and XB010 trials. The main forward-looking catalysts are zanzalintinib, for which an NDA with atezolizumab in previously treated metastatic colorectal cancer was accepted with a PDUFA target action date of December 3, 2026, and STELLAR-304 top-line results expected in mid-2026. Investors face material risks from generic cabozantinib competition: multiple ANDA and 505(b)(2) filers have Paragraph IV challenges to CABOMETYX patents, with a consolidated trial scheduled for November 2, 2026, and the composition-of-matter patent with term extension expires in August 2026. The company also faces U.S. drug pricing policy and 340B Program litigation risks.
Exelixis 8-K Report, Financial Results (Jan 12, 2026)
Exelixis, Inc. (Nasdaq: EXEL) furnished this Form 8-K under Item 2.02 to report preliminary, unaudited financial results for the fiscal year 2025 (ended January 2, 2026), provide fiscal 2026 financial guidance, and deliver a business update. The company reported approximately $2.123 billion in preliminary U.S. net product revenues for the cabozantinib franchise in fiscal 2025, with total revenues of approximately $2.320 billion. Fiscal 2026 guidance calls for total revenues of $2.525 billion to $2.625 billion and net product revenues of $2.325 billion to $2.425 billion. The guidance does not reflect any revenue from a potential U.S. launch of zanzalintinib in previously treated metastatic colorectal cancer, which is under FDA review in combination with atezolizumab. The audit of the fiscal 2025 financial statements is ongoing and could change the figures, and Exelixis plans to report audited results on February 10, 2026. The update outlines 2026 priorities centered on growing CABOMETYX in renal cell carcinoma and neuroendocrine tumors, advancing zanzalintinib through several pivotal trials (STELLAR-303 and STELLAR-304 topline data expected mid-2026), and progressing early-stage pipeline assets. The company also disclosed that it has repurchased $2.16 billion of common stock since March 2023 and authorized up to an additional $750 million in repurchases before December 31, 2026. The filing states that the preliminary results have not been audited or reviewed by the independent registered public accounting firm and may differ materially from the audited financial statements. The information is furnished rather than filed for purposes of Section 18 of the Exchange Act.
Exelixis 8-K Report, Executive Changes (Nov 7, 2025)
Exelixis, Inc. (EXEL) disclosed in this Form 8-K, filed November 7, 2025, that Jeffrey Hessekiel, J.D., Executive Vice President and General Counsel, notified the Company on November 4, 2025 of his intention to resign. He will cease serving as General Counsel effective November 7, 2025, and his resignation is stated not to result from any disagreement with the Company. The Company also announced that Brenda Hefti, J.D., Ph.D., Senior Vice President, Intellectual Property (IP) & Licensing, will be promoted to General Counsel effective November 7, 2025. She will report to Michael Morrissey, Ph.D., President and Chief Executive Officer. Dr. Hefti joined the Company in 2013 as corporate counsel, became Head of IP in 2014, and has served as Senior Vice President, IP & Licensing since 2020. For investors, the filing is a planned leadership transition within the legal function, with an internal successor already named and effective on the same date as the departure. The filing does not disclose any change to compensation arrangements or any other financial or operational terms.
Exelixis Quarterly Report for Q3 Ended Oct 3, 2025
Exelixis, Inc. reported third-quarter 2025 total revenues of $597.8 million, up from $539.5 million a year earlier, driven by net product revenues of $542.9 million, which rose from $478.1 million. Net product revenues were primarily CABOMETYX, at $539.9 million for the quarter. Collaboration revenues declined to $54.8 million from $61.5 million, as license revenues fell with fewer milestones. Income from operations was $236.5 million, versus $136.1 million a year earlier, and net income was $193.6 million, or $0.69 per diluted share, compared with $118.0 million, or $0.40 per diluted share. The quarter included $19.8 million in restructuring expenses tied to the 2025 Plan, which closed the King of Prussia, Pennsylvania office. For the nine months ended September 30, 2025, net cash from operating activities was $550.8 million. Cash, cash equivalents and marketable securities totaled $1.6 billion, down from $1.7 billion at December 31, 2024, mainly because of $689.9 million in share repurchase payments. As of September 30, 2025, $104.7 million remained under existing repurchase authorizations, and in October 2025 the board authorized an additional $750.0 million through December 31, 2026. Management states that current resources should fund operations for at least 12 months. The filing highlights pending generic challenges to CABOMETYX, including ANDA litigation with MSN, Sun, and Azurity, with trial scheduled for November 2, 2026. Exelixis settled with Biocon, which will be licensed to market a generic version in the U.S. beginning January 1, 2031. The company also reported positive top-line results from the STELLAR-303 phase 3 trial of zanzalintinib, and it intends to file a New Drug Application by the end of 2025, subject to the availability of government services.
Exelixis 8-K Report, Financial Results (Nov 4, 2025)
Exelixis, Inc. (Exelixis) reported financial results for the quarter ended September 30, 2025 (the company's fiscal quarter ended October 3, 2025), with total revenues of $597.8 million, including net product revenues of $542.9 million from the cabozantinib franchise in the U.S. GAAP net income was $193.6 million, or $0.69 per diluted share, compared with $118.0 million, or $0.40 per diluted share, in the prior-year quarter. Non-GAAP net income, which excludes stock-based compensation net of tax, was $217.9 million, or $0.78 per diluted share. Collaboration revenues declined to $54.8 million from $61.5 million, mainly due to lower milestone-related revenue and development cost reimbursements. Restructuring expenses were $19.8 million, tied to a workforce reorganization and the closure of the King of Prussia, Pennsylvania office, with aggregate charges estimated at approximately $20.5 million. The company updated its fiscal 2025 guidance, raising total revenues to $2.30 billion to $2.35 billion (from $2.25 billion to $2.35 billion) and net product revenues to $2.10 billion to $2.15 billion. It also lowered its R&D expense guidance to $850 million to $900 million and its effective tax rate guidance to 17% to 18%. On the pipeline front, Exelixis intends to submit a New Drug Application for zanzalintinib with atezolizumab in previously treated metastatic colorectal cancer in the U.S. by the end of 2025, following STELLAR-303 results that met one dual primary endpoint. The filing also reports the Board authorized a new stock repurchase program of up to $750 million before December 31, 2026. The filing discloses that the company's Board authorized the new repurchase program in October 2025, and that as of September 30, 2025, Exelixis had repurchased $895.3 million of its common stock under prior programs at an average price of $37.18 per share. Investors should weigh the strong product revenue growth and new buyback authorization against the decline in collaboration revenue and the pending regulatory submission for zanzalintinib, which the company noted may be affected by U.S. federal government shutdown limitations on FDA services.
Exelixis 8-K Report, Executive Changes (Aug 29, 2025)
Exelixis, Inc. filed a Form 8-K on August 29, 2025 reporting two executive leadership changes under Item 5.02. On August 29, 2025, the Board of Directors appointed Dana T. Aftab, Ph.D., the Company's current Executive Vice President, Discovery and Translational Research and Chief Scientific Officer, as Executive Vice President, Research and Development. Information about Dr. Aftab's background, compensatory arrangements, and related party transactions is incorporated by reference from the Company's definitive proxy statement on Schedule 14A filed April 16, 2025. Also effective August 29, 2025, Amy C. Peterson, M.D., concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer. In connection with her departure, Dr. Peterson is entitled to payments under the Company's Change in Control and Severance Benefit Plan, as amended and restated, and applicable law. The filing does not state the amount of those payments. For investors, the filing signals a reshuffling of the senior research and medical leadership team, with the research chief taking an expanded R&D role and the chief medical officer position being vacated. The filing does not describe the reasons for the departure or any succession plan for the Chief Medical Officer role.
Exelixis 8-K Report, Financial Results (Jul 28, 2025)
Exelixis, Inc. (Nasdaq: EXEL) reported financial results for the quarter ended June 30, 2025 (fiscal quarter ended July 4, 2025) and provided a corporate update in a press release furnished as Exhibit 99.1. Total revenues were $568.3 million, compared with $637.2 million a year earlier, and net product revenues rose to $520.0 million from $437.6 million, primarily on higher sales volume. Collaboration revenues fell to $48.2 million from $199.6 million, reflecting a $150.0 million commercial milestone recognized in the second quarter of 2024. GAAP net income was $184.8 million, or $0.65 per diluted share, versus $226.1 million, or $0.77 per diluted share, in the prior-year quarter; non-GAAP diluted EPS was $0.75 compared with $0.84. The company maintained its full-year 2025 guidance, with total revenues of $2.25 billion to $2.35 billion and net product revenues of $2.05 billion to $2.15 billion. The release highlights pipeline and regulatory developments. Positive top-line results from the phase 3 STELLAR-303 trial of zanzalintinib plus atezolizumab in metastatic colorectal cancer showed a statistically significant overall survival improvement versus regorafenib in the intent-to-treat population, and Exelixis plans to discuss the results with regulators. Enrollment in the STELLAR-304 pivotal trial in non-clear cell renal cell carcinoma was completed in May 2025, with top-line results expected in the first half of 2026. Exelixis decided not to proceed to phase 3 in the STELLAR-305 head and neck program and discontinued the XL495 program. The company also announced the initiation of the STELLAR-311 pivotal trial in advanced neuroendocrine tumors, and a settlement with Biocon Pharma allowing a generic CABOMETYX launch in the U.S. beginning January 1, 2031, subject to FDA approval and conditions. Capital allocation and tax items were also disclosed. Under its stock repurchase programs, Exelixis had repurchased $796.3 million of common stock at an average price of $36.69 per share as of June 30, 2025, and weighted-average diluted shares decreased to 284.4 million in the quarter. The company estimated a federal cash tax benefit of $147 million from accelerated deduction of previously unamortized domestic R&E expenditures under the One Big Beautiful Bill Act, with no corresponding impact to the federal income tax provision.
Exelixis Quarterly Report for Q2 Ended Jul 4, 2025
Exelixis, Inc. reported second-quarter 2025 total revenues of $568.3 million, down from $637.2 million in the second quarter of 2024, while net product revenues rose to $520.0 million from $437.6 million. Net income for the quarter was $184.8 million, or $0.65 per share on a diluted basis, compared with $226.1 million, or $0.77 per share diluted, a year earlier. For the six months ended June 30, 2025, total revenues were $1.12 billion and net income was $344.5 million. Growth in CABOMETYX net product revenues was driven by continued demand for the nivolumab combination in first-line advanced renal cell carcinoma, and the company projects net product revenues may increase for the remainder of 2025 following the first-quarter 2025 FDA approval for previously treated advanced neuroendocrine tumors. Collaboration revenues fell to $48.2 million in the quarter from $199.6 million, reflecting the $150.0 million Ipsen commercial milestone recognized in the prior-year period. Cash, cash equivalents and marketable securities totaled $1.39 billion at June 30, 2025, down from $1.75 billion at December 31, 2024, primarily due to share repurchases. The company repurchased $796.3 million of common stock under two $500.0 million authorizations, leaving approximately $203.7 million available through December 31, 2025. Management states that current cash and marketable securities, together with net product and collaboration revenues, will enable it to maintain operations for at least 12 months. Research and development expenses were $200.4 million in the quarter, and the company expects clinical trial costs to increase for the remainder of 2025, driven mainly by zanzalintinib studies. The filing also discusses significant patent litigation over CABOMETYX generics. In July 2025, Exelixis entered into a settlement and license agreement with Biocon that grants a U.S. generic license beginning January 1, 2031, subject to FDA approval. Litigation with MSN, Sun and Azurity remains ongoing, and the company states it is not possible at this time to determine the likelihood of an unfavorable outcome. The company also reported positive top-line results from the STELLAR-303 phase 3 trial of zanzalintinib in June 2025 and intends to discuss a New Drug Application filing with U.S. regulators.
Exelixis 8-K Report, Shareholder Vote Results (Jun 2, 2025)
Exelixis held its Annual Meeting of Stockholders via live webcast on May 28, 2025. Stockholders took three actions: they elected all 11 nominated directors to serve until the 2026 annual meeting, ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending January 2, 2026, and approved, on an advisory basis, the compensation of the named executive officers as disclosed in the proxy statement (Say on Pay). For each director, votes in favor ranged from 214,815,636 (Stelios Papadopoulos, Ph.D.) to 224,162,314 (David E. Johnson), with 23,953,528 broker non-votes recorded for each director. Papadopoulos received the highest number of votes against (11,003,480), while Tomas J. Heyman received 7,857,654 votes against. The auditor ratification received 243,302,343 votes for and 6,391,854 against. The Say on Pay proposal received 218,948,303 votes for and 6,761,611 against, with 288,538 abstentions and 23,953,528 broker non-votes. The filing reports voting results only and contains no new financial results, guidance, or strategic announcements. Investors should note the comparatively higher opposition to Papadopoulos and Heyman among the director votes, and the Say on Pay outcome, as indicators of stockholder sentiment on governance and compensation.
Exelixis Quarterly Report for Q1 Ended Apr 4, 2025
Exelixis, Inc. reported first-quarter 2025 total revenues of $555.4 million, up from $425.2 million a year earlier, driven by net product revenues of $513.3 million compared with $378.5 million. CABOMETYX net product revenues were $510.9 million, and the filing attributes the increase primarily to a 25% increase in CABOMETYX units sold and a 9% increase in average net selling price. Net income was $159.6 million, or $0.55 per diluted share, versus $37.3 million, or $0.12 per share, in the prior-year quarter. The prior-year period included $32.8 million in restructuring expenses, which were absent in 2025. Research and development expenses declined to $212.2 million from $227.7 million, while selling, general and administrative expenses rose to $137.2 million from $114.0 million. Cash flow from operations was $211.4 million, compared with $68.8 million a year earlier. The company ended the quarter with $1.65 billion in cash, cash equivalents and marketable securities, down from $1.75 billion at year-end 2024, after repurchasing $283.9 million of common stock in cash during the quarter. Under two authorizations totaling $1.0 billion, $494.5 million of stock has been repurchased to date, leaving about $505.5 million available through December 31, 2025. The company states it expects its current resources to fund operations for at least 12 months. The filing highlights ongoing patent litigation over CABOMETYX. Multiple generic ANDA filers (MSN, Sun, Biocon) and Azurity's 505(b)(2) application have filed Paragraph IV certifications, and the company has sued each of them. In the MSN II case, the Delaware District Court ruled in October 2024 that the effective date of any FDA approval of MSN's ANDA would not be earlier than January 15, 2030, and MSN has appealed. The company also reported an FDA approval in March 2025 for CABOMETYX in previously treated advanced neuroendocrine tumors, and it stated that it expects net product revenues to increase for the remainder of 2025 partly because of that approval.
Exelixis 8-K Report, Financial Results (May 13, 2025)
Exelixis, Inc. (Nasdaq: EXEL) reported first quarter 2025 financial results for the quarter ended April 4, 2025 (presented as March 31, 2025) and provided a corporate update, as furnished in Exhibit 99.1 press release dated May 13, 2025. Total revenues were $555.4 million versus $425.2 million in the prior-year period, driven by net product revenues of $513.3 million (up from $378.5 million), which the company attributed to higher sales volume and higher average net selling price. Collaboration revenues declined to $42.2 million from $46.7 million. GAAP net income was $159.6 million, or $0.55 per diluted share, compared with $37.3 million, or $0.12 per diluted share, a year earlier. Non-GAAP diluted EPS was $0.62. Management raised full-year 2025 guidance for total revenues to $2.25 billion-$2.35 billion (from $2.15 billion-$2.25 billion) and for net product revenues to $2.05 billion-$2.15 billion (from $1.95 billion-$2.05 billion). The release highlights the March 2025 U.S. FDA approval of CABOMETYX for previously treated pancreatic and extra-pancreatic neuroendocrine tumors, which management described as the launch of CABOMETYX in advanced NET. Management also outlined zanzalintinib pivotal readouts expected in the second half of 2025 from STELLAR-303 (colorectal cancer), STELLAR-304 (non-clear cell renal cell carcinoma), and a decision on moving into the phase 3 portion of STELLAR-305 (head and neck cancer), along with the planned STELLAR-311 pivotal study initiation in neuroendocrine tumors in the first half of 2025. The company discontinued development of the XL495 program based on early clinical data. Capital return was active during the quarter: Exelixis had repurchased $494.5 million of common stock at an average price of $34.87 per share under programs authorized in August 2024 and February 2025, each with a December 31, 2025 deadline. Weighted-average diluted shares declined to 288.2 million as of March 31, 2025, from 326.3 million at the start of the first program in March 2023.
Exelixis 8-K Report, Executive Changes (Mar 31, 2025)
Exelixis, Inc. filed this Form 8-K to report that on March 28, 2025, its Board of Directors, following a recommendation from the Compensation Committee, approved a Special Equity Award Program. The program grants a one-time performance-based restricted stock unit (PSU) award to all employees of the Company and its subsidiaries, including named executive officers, under the 2017 Equity Incentive Plan. The Board states the program is intended to incentivize long-term performance aligned with shareholder value and to retain employees over a five-year transformational period. For named executive officers, the filing states that award values equal approximately two times the value of an annual long-term incentive award for similarly situated executives at peer companies placed at the 50th percentile. The filing lists the number of PSU shares for Dr. Michael M. Morrissey (589,719), Mr. Christopher J. Senner (170,009), Dr. Dana T. Aftab (132,819), Mr. Jeffrey J. Hessekiel (154,070) and Dr. Amy C. Peterson (159,383). Vesting is tied to performance: the stock price must reach a volume-weighted average closing price of at least $60 per share over any consecutive 90-calendar-day period within the five-year performance period, and employees must generally remain employed through the fifth anniversary of the grant, subject to exceptions for qualifying terminations. If the price goal is not met within the performance period, the entire award is forfeited. The form of PSU agreement for employees at or above the vice president level is to be filed as an exhibit to the Form 10-Q for the period ending April 4, 2025.
Exelixis 8-K Report, Corporate Update (Feb 21, 2025)
Exelixis, Inc. (Nasdaq: EXEL) reported in this Form 8-K, filed February 21, 2025 for an event dated February 20, 2025, that its Board of Directors authorized the repurchase of up to an additional $500 million of its common stock before December 31, 2025. The announcement is furnished as Exhibit 99.1 to the filing and is made under Item 8.01 (Other Events). According to the accompanying press release, Exelixis plans to complete its currently ongoing $500 million stock repurchase program, announced in August 2024, in the second quarter of 2025, and to begin repurchases under the newly authorized program thereafter. The company states that the February 2025 program is the fourth such program undertaken since March 2023, and that it has returned over $1.2 billion to shareholders through these programs as of the end of fiscal year 2024. The press release says repurchases may be made through open market purchases, block trades, accelerated share repurchase transactions, exchange transactions, or a combination of these. Timing and amount will depend on capital needs, alternative investment opportunities, the stock price, and general market conditions. The filing also notes that the company's Annual Report on Form 10-K was filed with the SEC on February 11, 2025.
Exelixis 8-K Report, Financial Results (Feb 11, 2025)
Exelixis, Inc. (Nasdaq: EXEL) filed this Form 8-K under Item 2.02 to furnish its press release (Exhibit 99.1) reporting financial results for the fourth quarter and fiscal year ended January 3, 2025 (presented as December 31, 2024), along with a corporate update. Total revenues were $566.8 million for the quarter and $2,168.7 million for the year, up from $479.7 million and $1,830.2 million in the prior-year periods. Net product revenues were $515.2 million for the quarter and $1,809.4 million for the year, driven by higher sales volume and average net selling price. GAAP net income was $139.9 million ($0.48 diluted EPS) for the quarter and $521.3 million ($1.76 diluted EPS) for the year, while non-GAAP diluted EPS was $0.55 for the quarter and $2.00 for the year. The company maintained its 2025 guidance, which does not reflect any revenue from a potential U.S. approval of CABOMETYX in previously treated advanced neuroendocrine tumors. The FDA's PDUFA target action date for that sNDA is April 3, 2025. Guidance calls for total revenues of $2.15 billion to $2.25 billion and net product revenues of $1.95 billion to $2.05 billion. Management highlighted zanzalintinib pivotal milestones in the second half of 2025, including top-line STELLAR-303 and STELLAR-304 results, and a decision on advancing STELLAR-305, along with Merck-sponsored zanzalintinib and belzutifan renal cell carcinoma studies. Other items disclosed include $205.6 million of stock repurchases under the ongoing $500 million 2024-25 program at an average price of $33.62 per share as of fiscal year-end, and a Paragraph IV certification from MSN Pharmaceuticals against another cabozantinib Orange Book patent (expiring 2032), which Exelixis is evaluating. The District Court previously ruled in Exelixis' favor in the second ANDA litigation, with the MSN generic launch date not earlier than January 15, 2030, subject to appeal.
Exelixis Annual Report, Year Ended Jan 3, 2025
Exelixis, Inc. reported its eighth consecutive year of annual profitability for 2024, with net income of $521.3 million, or $1.76 per diluted share, compared with $207.8 million, or $0.65 per share, in 2023. Total revenues rose to $2,168.7 million from $1,830.2 million, driven by net product revenues of $1,809.4 million, almost entirely from CABOMETYX, and license revenues of $349.2 million, which include a $150.0 million commercial milestone from Ipsen. Fiscal 2024 was a 53-week year. The company ended the year with $1.7 billion in cash, cash equivalents and marketable securities and repurchased $652.0 million of its common stock during 2024 under two programs. The company's growth depends on CABOMETYX, which the filing says accounts for the majority of revenues. The filing notes that the CABOMETYX plus nivolumab first-line RCC combination drove the 8.2% increase in CABOMETYX units sold. Pipeline catalysts include the pending FDA decision on CABINET (pNET/epNET) with a PDUFA date of April 3, 2025, and the lead investigational asset zanzalintinib, with several pivotal trials ongoing. The company also reported that COSMIC-313 did not show an overall survival benefit and will not be pursued for marketing authorization. CONTACT-02 showed a non-significant overall survival trend. The filing also flags material risks. Generic challengers have filed ANDAs against CABOMETYX: MSN, Teva, Cipla and Sun. Settlements with Teva and Cipla allow generic entry beginning January 1, 2031, and a court judgment sets MSN's earliest effective approval date at January 15, 2030. The 340B Program Integrity Initiative is under challenge, and the IRA drug-pricing provisions create additional uncertainty. Management projects higher 2025 net product revenues, lower license revenues and higher R&D expense.
Exelixis 8-K Report, Financial Results (Jan 13, 2025)
Exelixis, Inc. filed this Current Report on Form 8-K under Item 2.02 to furnish a January 12, 2025 press release announcing preliminary, unaudited financial results for the fiscal year ended January 3, 2025, along with fiscal year 2025 financial guidance and an update on its business. The company stated that the audit of its fiscal 2024 financial statements is ongoing and could change the information in the press release, and that it will report audited results on February 11, 2025. Preliminary fiscal 2024 figures show total revenues of approximately $2.165 billion and net product revenues of approximately $1.805 billion, which the company describes as cabozantinib franchise U.S. net product revenues. Research and development expenses were approximately $910 million and selling, general and administrative expenses approximately $495 million, with ending cash and marketable securities of approximately $1.75 billion. Fiscal 2025 guidance calls for total revenues of $2.15 billion to $2.25 billion and net product revenues of $1.95 billion to $2.05 billion, with R&D expenses of $925 million to $975 million, SG&A of $475 million to $525 million, and an effective tax rate of 21% to 23%. The guidance does not reflect any revenue from a potential U.S. launch of CABOMETYX in previously treated advanced neuroendocrine tumors, for which the FDA has a PDUFA target action date of April 3, 2025. The press release also updates pipeline priorities, including expansion of the zanzalintinib pivotal program, early-stage data readouts expected in 2025, and planned IND filings for three biotherapeutic programs. The company has repurchased $205.6 million of stock under a program authorized for up to $500 million through the end of 2025. The information is furnished, not filed, under Item 2.02.
Exelixis Quarterly Report for Q3 Ended Sep 27, 2024
Exelixis, Inc. reported third-quarter 2024 total revenues of $539.5 million, up from $471.9 million in the third quarter of 2023, with net income of $118.0 million, or $0.40 per diluted share, compared with net income of $1.0 million in the prior-year quarter. Net product revenues were $478.1 million, driven by CABOMETYX, which generated $475.7 million in the quarter. For the nine months ended September 30, 2024, total revenues were $1.60 billion and net income was $381.4 million, aided by $299.9 million in license revenues, including a $150.0 million commercial milestone from Ipsen. Operating results also included a $51.7 million non-cash impairment charge related to Alameda leased facilities and $33.4 million in restructuring expenses under the 2024 Restructuring Plan. The company ended the quarter with $1.7 billion in cash, cash equivalents and marketable securities, unchanged in total from December 31, 2023, after repurchasing $461.6 million of common stock in the nine-month period. Management states that current resources should fund operations for at least 12 months. A new $500 million share repurchase authorization was approved in August 2024, with approximately $487.6 million remaining as of September 30, 2024. Investors should note the ongoing generic competition risk to CABOMETYX. The company has settled litigation with Teva and Cipla with licenses beginning January 1, 2031, and a Delaware court ruled in October 2024 that generic entry under MSN's ANDA cannot occur before January 15, 2030. Sun Pharmaceutical Industries also filed a Paragraph IV notice in September 2024, which the company is evaluating. Pipeline activity includes the sNDA for cabozantinib in pNET/epNET with a PDUFA target action date of April 3, 2025, and the phase 3 STELLAR-303 trial for zanzalintinib, with preliminary results expected in 2025.
Exelixis 8-K Report, Financial Results (Oct 29, 2024)
Exelixis, Inc. furnished a press release under Item 2.02 reporting its results for the quarter ended September 27, 2024 (presented as September 30, 2024) and providing a corporate update. Total revenues were $539.5 million, including net product revenues of $478.1 million, compared with $471.9 million total revenues in the prior-year period. GAAP net income was $118.0 million, or $0.40 per diluted share, versus $1.0 million in the prior-year quarter. Non-GAAP net income was $135.7 million, or $0.47 per diluted share. The quarter included a $51.7 million non-cash impairment charge on leased facilities not in use, and research and development expenses fell to $222.6 million from $332.6 million. The company raised its 2024 guidance. Total revenues are now expected at $2.150 billion to $2.200 billion (previously $1.975 billion to $2.075 billion), and net product revenues at $1.775 billion to $1.825 billion (previously $1.650 billion to $1.750 billion). The filing also reports a favorable October 2024 District Court ruling rejecting MSN's challenge to three cabozantinib patents, which expire January 15, 2030, and a new Merck collaboration to evaluate zanzalintinib with KEYTRUDA in head and neck cancer and with WELIREG in renal cell carcinoma. Exelixis has repurchased $12.4 million of stock under a $500 million program authorized through the end of 2025. Pipeline and regulatory milestones include an FDA sNDA for cabozantinib in advanced neuroendocrine tumors with a PDUFA target action date of April 3, 2025, a planned sNDA for cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer in the fourth quarter of 2024, and preliminary STELLAR-303 results expected in 2025. Ipsen submitted a European extension of indication application for CABOMETYX in neuroendocrine tumors.
Exelixis 8-K Report, Corporate Update (Oct 15, 2024)
Exelixis, Inc. (EXEL) reported in this Form 8-K, filed October 15, 2024, under Item 8.01 (Other Events), that on October 14, 2024 it entered into a clinical development collaboration with Merck & Co., Inc., known as MSD outside of the United States and Canada. The collaboration covers Exelixis' investigational tyrosine kinase inhibitor zanzalintinib combined with Merck's KEYTRUDA (pembrolizumab) in a phase 3 pivotal trial for head and neck squamous cell carcinoma (HNSCC), and zanzalintinib combined with WELIREG (belzutifan), Merck's oral HIF-2α inhibitor, in a phase 1/2 trial and two phase 3 pivotal trials for renal cell carcinoma (RCC). Under the terms, Merck will supply KEYTRUDA for the ongoing, Exelixis-sponsored phase 3 STELLAR-305 pivotal trial in previously untreated PD-L1 positive recurrent or metastatic HNSCC. Merck will sponsor the phase 1/2 trial and two phase 3 pivotal RCC trials, fund one of the phase 3 studies, and Exelixis will co-fund the phase 1/2 trial and the other phase 3 study while also supplying zanzalintinib and cabozantinib. Exelixis retains all global commercial and marketing rights to zanzalintinib. The filing is a notice of a clinical development collaboration and includes standard forward-looking statement cautions. It does not state financial terms of the collaboration, such as payments or cost amounts.
Exelixis 8-K Report, Corporate Update (Oct 15, 2024)
Exelixis, Inc. (Exelixis) reported in this Form 8-K, filed under Item 8.01 (Other Events), that the U.S. District Court for the District of Delaware issued a ruling in its two consolidated patent lawsuits against MSN Pharmaceuticals, Inc. (together with certain affiliates, including MSN Laboratories Private Limited, referred to as MSN). The court rejected MSN's invalidity challenge to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, which expire January 15, 2030. MSN had previously stipulated that its proposed Abbreviated New Drug Application (ANDA) product infringes these patents. The court also found that Exelixis' U.S. Patent No. 11,298,349 is not invalid and that MSN's proposed ANDA product does not infringe it; this patent expires February 10, 2032. The court asked the parties to jointly submit a final judgment reflecting the opinion by October 22, 2024. Based on the ruling, the effective date of any final FDA approval of MSN's ANDA shall not be earlier than January 15, 2030, the expiration date of the three patents that were upheld. The filing includes forward-looking statements, including on the potential timing of MSN's commercial launch of its proposed generic product in the United States, and refers readers to the Risk Factors sections of Exelixis' most recent Form 10-K and subsequent Forms 10-Q for relevant risks.
Exelixis 8-K Report, Financial Results (Aug 6, 2024)
Exelixis, Inc. (Nasdaq: EXEL) reported second quarter 2024 financial results for the quarter ended June 28, 2024, per Exhibit 99.1 press release dated August 6, 2024. Total revenues were $637.2 million, up from $469.8 million in the prior-year quarter, with net product revenues of $437.6 million (versus $409.6 million) and collaboration revenues of $199.6 million (versus $60.2 million), driven mainly by milestone-related revenue and higher ex-U.S. royalties. GAAP net income was $226.1 million, or $0.77 per diluted share, compared with $81.2 million, or $0.25 per diluted share, a year earlier. Non-GAAP diluted EPS, which excludes stock-based compensation net of tax, was $0.84. Research and development expenses were $211.1 million and SG&A expenses were $132.0 million. The quarter included a $150 million commercial milestone from partner Ipsen, based on $600 million in cumulative cabozantinib net sales over four consecutive quarters, with payment expected in the third quarter of 2024. The FDA accepted the cabozantinib supplemental New Drug Application for previously treated advanced neuroendocrine tumors under standard review, with a PDUFA target action date of April 3, 2025. Management also updated 2024 guidance, now calling for total revenues of $1.975 billion to $2.075 billion and net product revenues of $1.650 billion to $1.750 billion. On capital allocation, Exelixis completed its $450 million 2024 stock repurchase program, repurchasing 20.3 million shares, and the Board authorized up to an additional $500 million of repurchases through the end of 2025. The company also announced a pipeline prioritization: it will discontinue XB002, plans a new phase 3 trial of zanzalintinib in neuroendocrine tumors (STELLAR-311) in the first half of 2025, and is advancing XL309 and XB010. It also settled CABOMETYX patent litigation with Cipla, with a license for generic entry in the U.S. beginning January 1, 2031, if approved.
Exelixis Quarterly Report for Q2 Ended Jun 28, 2024
Exelixis, Inc. reported a strong second quarter of 2024, with total revenues of $637.2 million for the three months ended June 30, 2024, up from $469.8 million a year earlier, and net income of $226.1 million, or $0.77 per diluted share, compared with $81.2 million, or $0.25 per diluted share, in the prior-year quarter. The result was driven largely by license revenues of $195.0 million, which include a $150.0 million commercial milestone from Ipsen tied to $600.0 million in cumulative cabozantinib net sales over four consecutive quarters. Net product revenues rose to $437.6 million from $409.6 million, with CABOMETYX sales increasing on higher unit volume following the approval of CABOMETYX in combination with nivolumab for first-line advanced RCC. For the six months ended June 30, 2024, total revenues were $1.06 billion and net income was $263.4 million. Results for the period also reflect $33.3 million in restructuring expenses under the 2024 Restructuring Plan, which was substantially completed by the end of the second quarter. Cash, cash equivalents and investments totaled $1.4 billion at June 30, 2024, down from $1.7 billion at December 31, 2023, reflecting $450.0 million of share repurchases completed under the program authorized in January 2024. In August 2024, the Board authorized a new repurchase program of up to $500.0 million through the end of 2025. The filing also highlights ongoing legal and pipeline developments. Settlements with Cipla and earlier with Teva provide U.S. generic entry for CABOMETYX no earlier than January 1, 2031, while the MSN II litigation remains pending with a judgment expected in the second half of 2024. On the pipeline side, the company reported an FDA-accepted sNDA for cabozantinib in pNET and epNET with a PDUFA date of April 3, 2025, and is discontinuing XB002 and prioritizing zanzalintinib, XL309 and XB010.
Exelixis 8-K Report, Executive Changes (Jun 3, 2024)
Exelixis, Inc. filed this Current Report on Form 8-K to report the results of its 2024 Annual Meeting of Stockholders, held May 30, 2024 via live webcast. The filing discloses two items: Item 5.02 and Item 5.07. The main action was stockholder approval of an amendment and restatement of the Exelixis, Inc. 2000 Employee Stock Purchase Plan (the Amended ESPP), which took effect immediately upon approval. The amendment was made primarily to increase the number of shares of common stock authorized for issuance under the plan by 6,000,000 shares. The filing states that the material terms are summarized in the definitive proxy statement filed April 18, 2024, and that the Amended ESPP is filed as Appendix A to that proxy statement. Stockholders also elected 11 directors to serve until the 2025 annual meeting, ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending January 3, 2025, and approved, on an advisory basis, the compensation of the named executive officers (Say on Pay). Each proposal was approved, with vote counts for and against reported in the filing.
Exelixis 8-K Report, Corporate Update (May 20, 2024)
On May 20, 2024, Exelixis, Inc. announced that it has entered into a Settlement and License Agreement with Cipla Ltd. and Cipla USA, Inc. The agreement resolves two patent litigations Exelixis brought in response to Cipla's Abbreviated New Drug Application seeking approval to market generic versions of CABOMETYX (cabozantinib) tablets in the 20 mg, 40 mg and 60 mg strengths before the expiration of the applicable patents. Under the terms of the agreement, Exelixis will grant Cipla a license to market generic versions of CABOMETYX in the United States beginning on January 1, 2031, if approved by the U.S. Food and Drug Administration and subject to conditions and exceptions common to agreements of this type. The parties will also terminate all ongoing Hatch-Waxman Act litigation between them regarding CABOMETYX patents pending in the U.S. District Court for the District of Delaware, with the lawsuits to be dismissed after a period of time to allow for review by the Federal Trade Commission. The agreement is confidential and subject to review by the FTC and the U.S. Department of Justice. The filing includes forward-looking statements about Exelixis' obligations under the agreement, and identifies Exelixis' ability to meet those obligations as a key risk factor.
Exelixis 8-K Report, Corporate Update (May 10, 2024)
Exelixis, Inc. (EXEL) filed a Form 8-K on May 10, 2024 under Item 8.01 (Other Events) to disclose patent litigation related to CABOMETYX (cabozantinib) tablets. On March 27, 2024, the company received notice from Cipla Ltd. and Cipla USA, Inc. that Cipla had amended its Abbreviated New Drug Application (ANDA), originally filed with the FDA more than one year earlier, to add Paragraph IV certifications. The amended ANDA seeks approval to market generic CABOMETYX in 20 mg and 40 mg strengths, in addition to the 60 mg strength in the original application, before the expiration of seven listed U.S. patents. On May 9, 2024, Exelixis filed a patent infringement complaint in the U.S. District Court for the District of Delaware against Cipla. The complaint asserts five of the patents (Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349) arising from the amended ANDA filing. Among other relief, Exelixis seeks an order that any FDA approval of Cipla's ANDA take effect no earlier than the expiration of all five asserted patents, the latest of which expires on February 10, 2032, along with equitable relief enjoining Cipla from infringing these patents. For investors, the filing signals that Exelixis is actively defending CABOMETYX's patent protection against a generic challenger. The filing does not state the financial impact of the litigation or the outcome of any proceeding, and it describes only the legal actions and the relief sought.
Exelixis Quarterly Report for Q1 Ended Mar 29, 2024
Exelixis, Inc. reported total revenues of $425.2 million for the first quarter of 2024, up from $408.8 million in the prior-year quarter, with net product revenues of $378.5 million, up from $363.4 million. CABOMETYX accounted for $376.4 million of net product revenues. Net income was $37.3 million, or $0.12 per share basic and diluted, compared with $40.0 million, or $0.12 per share, a year earlier. The quarter included $32.8 million of restructuring expenses tied to the 2024 Restructuring Plan, which is intended to reduce the workforce and rebalance the cost structure. Research and development expenses fell to $227.7 million from $234.2 million, and selling, general and administrative expenses fell to $114.0 million from $131.4 million. Cash, cash equivalents and investments totaled $1.6 billion at March 31, 2024, compared with $1.7 billion at December 31, 2023. Net cash provided by operating activities was $68.8 million, down from $84.4 million, and the company paid $185.4 million to repurchase common stock. Under a stock repurchase program authorized in January 2024 for up to $450 million before the end of 2024, the company repurchased 8.6 million shares for an aggregate $190.7 million, leaving approximately $259.3 million available. Total stockholders' equity declined to $2.13 billion from $2.26 billion, and the accumulated deficit increased to $258.9 million. The filing highlights ongoing patent litigation over CABOMETYX. A bench trial in the MSN II case occurred in October 2023, with a judgment expected during the first half of 2024. On March 27, 2024, Cipla amended its ANDA to add further Paragraph IV certifications, which the company is evaluating. The filing states that any generic CABOMETYX approved and launched before patent expiration could significantly decrease U.S. revenues. The company also disclosed a settlement with Teva that grants Teva a license to market a generic CABOMETYX in the U.S. beginning January 1, 2031, if approved by the FDA.
Exelixis 8-K Report, Financial Results (Apr 30, 2024)
Exelixis, Inc. (Nasdaq: EXEL) reported first-quarter 2024 results for the quarter ended March 29, 2024, as stated in Item 2.02 of this 8-K, which furnishes a press release (Exhibit 99.1) dated April 30, 2024. Total revenues were $425.2 million, compared with $408.8 million a year earlier. Net product revenues were $378.5 million, up from $363.4 million, driven mainly by higher sales volume partially offset by lower average net selling price. GAAP net income was $37.3 million, or $0.12 per diluted share, versus $40.0 million, or $0.12, in the prior-year period. Non-GAAP net income, which excludes stock-based compensation net of tax, was $52.0 million, or $0.17 per diluted share. The company recorded $32.8 million in restructuring expenses, primarily severance and employee-related costs, asset impairment and contract termination costs. Exelixis maintained its fiscal 2024 guidance, which excludes restructuring costs from the January 2024 restructuring plan: total revenues of $1.825 billion to $1.925 billion, net product revenues of $1.650 billion to $1.750 billion, R&D expenses of $925 million to $975 million, SG&A expenses of $425 million to $475 million, and an effective tax rate of 20% to 22%. Cabozantinib franchise U.S. net product revenues were $378.5 million, and royalty revenues earned were $39.6 million. Management also cited Phase 3 CONTACT-02 (cabozantinib plus atezolizumab in mCRPC) PFS results and four-year CheckMate -9ER follow-up data, a ruling expected in spring 2024 in the second bench trial with MSN Pharmaceuticals, and a plan to repurchase up to an additional $450 million of stock before the end of 2024. The filing also describes pipeline priorities for 2024, including zanzalintinib pivotal trials, the XB002 ADC and XL309 USP1 inhibitor Phase 1 studies, and up to three Investigational New Drug filings this year, pending supportive preclinical data.
Exelixis 8-K Report, Executive Changes (Mar 29, 2024)
Exelixis, Inc. filed this Form 8-K under Item 5.02 to disclose a board change. On March 27, 2024, director Jacqueline Wright notified the Company that she will not stand for re-election to the Board of Directors when her term expires at the Company's 2024 annual meeting of stockholders. She will continue to serve as a director until that meeting. According to the filing, Ms. Wright's decision was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. The filing contains no financial results, guidance, or other operational disclosures. For investors, the filing is a governance notice. It signals a planned board departure at the 2024 annual meeting but does not name a successor or describe any compensatory arrangements.
Exelixis Annual Report, Year Ended Dec 29, 2023
Exelixis, Inc. reported its seventh consecutive year of annual profitability in 2023, with net income of $207.8 million ($0.65 per share, basic and diluted), compared with $182.3 million in 2022. Total revenues were $1,830.2 million versus $1,611.1 million, and net product revenues were $1,628.9 million, up 16% year over year. CABOMETYX drove the result, with net product revenues of $1,614.9 million, and the filing attributes the growth to a 9% increase in units sold following the FDA approval of CABOMETYX in combination with nivolumab for first-line advanced RCC, plus a 7% increase in average net selling price. Royalties earned on ex-U.S. cabozantinib sales were $148.5 million, up from $121.4 million. Operating expenses rose, with research and development expenses of $1,044.1 million (versus $891.8 million) and selling, general and administrative expenses of $542.7 million (versus $459.9 million). Interest income more than doubled to $86.5 million. Cash, cash equivalents and investments totaled $1.7 billion at year-end, down from $2.1 billion, mainly because the company repurchased $550.4 million of common stock during 2023. In January 2024 the Board authorized a further repurchase of up to $450.0 million and the company announced a restructuring that reduces its workforce by about 175 employees, or 13% of headcount, and terminates several research collaborations. The pipeline's key near-term events include the CONTACT-02 phase 3 trial in mCRPC, which met one of two primary endpoints (PFS), with overall survival still pending; the CABINET phase 3 trial in neuroendocrine tumors, where the company is discussing a potential FDA submission in 2024; and the zanzalintinib program, now in phase 3 trials. Investors should also note the risk from generic competition: ANDAs from MSN, Teva and Cipla challenge CABOMETYX patents, and the company settled with Teva in July 2023 on a license effective January 1, 2031. The MSN II bench trial occurred in October 2023 with judgment expected in the first half of 2024.
Exelixis 8-K Report, Financial Results (Feb 6, 2024)
Exelixis, Inc. (Nasdaq: EXEL) filed this Item 2.02 Form 8-K on February 6, 2024 to furnish a press release (Exhibit 99.1) reporting financial results for the fourth quarter and fiscal year ended December 29, 2023 (presented as December 31, 2023) and providing a corporate update. Total revenues were $479.7 million for the fourth quarter and $1,830.2 million for fiscal 2023, compared with $423.9 million and $1,611.1 million in the prior-year periods. Net product revenues were $429.3 million for the quarter and $1,628.9 million for the year, driven by higher sales volume and higher average net selling price. GAAP net income was $85.5 million ($0.27 per diluted share) for the quarter and $207.8 million ($0.65 per diluted share) for the year, while non-GAAP diluted EPS was $0.33 for the quarter and $0.90 for the year. For 2024, the company maintained its prior guidance: total revenues of $1.825 billion to $1.925 billion, net product revenues of $1.650 billion to $1.750 billion, and research and development expenses of $925 million to $975 million, excluding costs related to the restructuring plan announced in January 2024. Management highlighted planned regulatory strategies for cabozantinib in neuroendocrine tumors and metastatic castration-resistant prostate cancer, and an anticipated ruling in the second bench trial in the MSN Pharmaceuticals litigation in spring 2024. The board authorized up to an additional $450 million in share repurchases before the end of 2024, following completion of $550 million under the prior program.
Exelixis 8-K Report, Financial Results (Jan 8, 2024)
Exelixis, Inc. (Nasdaq: EXEL) filed this Form 8-K on January 8, 2024 to report preliminary, unaudited financial results for the fiscal year ended December 29, 2023, provide fiscal 2024 guidance, and disclose several corporate actions. Preliminary total revenues were approximately $1,830 million and net product revenues approximately $1,630 million for 2023, with R&D expenses of approximately $1,045 million and SG&A of approximately $545 million. For 2024, the company guided to total revenues of $1,825 million to $1,925 million, net product revenues of $1,650 million to $1,750 million, R&D expenses of $925 million to $975 million, and SG&A expenses of $425 million to $475 million. The audited results are scheduled for release on February 6, 2024, and the filing states the audit is ongoing and could change the preliminary figures. Exelixis's Board authorized a restructuring plan on January 5, 2024 to reduce its workforce by approximately 175 employees, or 13% of year-end 2023 headcount, and to reduce real estate commitments and terminate certain licensing partnerships. The company estimates aggregate charges of approximately $25 million, of which $13.5 million relates to the workforce reduction, substantially recognized in the first quarter of 2024. The Board also authorized up to $450 million in share repurchases during 2024, following the completion of $550 million in repurchases in 2023 that retired 26.2 million shares, or 8% of shares outstanding. Governance changes include the expansion of the Board to 13 members and the appointment of Mary C. Beckerle, Ph.D. and S. Gail Eckhardt, M.D. as directors. Director Alan M. Garber, M.D., Ph.D. will not stand for re-election at the 2024 annual meeting. The filing also outlines 2024 milestones, including the ASCO GU presentation of CONTACT-02 data, a pending ruling in the ANDA litigation with MSN Pharmaceuticals expected in the first half of 2024, and planned IND filings for several pipeline programs.
Exelixis 8-K Report, Executive Changes (Dec 20, 2023)
Exelixis, Inc. (the "Company") reported in this Form 8-K filed December 20, 2023 two governance-related actions taken by its Board of Directors effective December 14, 2023. First, the Board amended and restated the Exelixis, Inc. Change in Control and Severance Benefit Plan. Key changes include redefining "Change in Control Termination" as a Covered Termination (an involuntary termination without Cause or a Constructive Termination) occurring within three months before or fifteen months after a Change in Control; extending Covered Termination to include a Constructive Termination outside the Change in Control Period; setting the Severance Period for the Chief Executive Officer at 18 months for terminations outside that period; and providing a pro-rata portion of the Annual Bonus, based on actual Company performance, for terminations outside the Change in Control Period. The full amended Plan is to be filed as an exhibit to the Company's Form 10-K for the fiscal year ending December 29, 2023. Second, the Board amended and restated the Company's Bylaws, effective the same date. The revisions update advance notice procedures for stockholder director nominations and proposals to reflect the SEC's universal proxy rules (Rule 14a-19), change the advance notice window to generally between the 120th and 90th day before the first anniversary of the prior annual meeting, eliminate the requirement to provide a stockholder list at annual meetings, and clarify procedures for adjourned virtual meetings. For the 2024 Annual Meeting, stockholder nominations and proposals must be received no earlier than February 1, 2024 and no later than March 2, 2024. The Amended and Restated Bylaws are filed as Exhibit 3.1. The filing does not disclose any financial results, financial impact, or specific individual executive payments. Its main investor relevance lies in changes to executive severance protections and stockholder engagement mechanics.
Exelixis 8-K Report, Financial Results (Nov 1, 2023)
Exelixis, Inc. furnished a press release under Item 2.02 announcing financial results for the quarter ended September 29, 2023 (reported as September 30, 2023) and a corporate update. Total revenues were $471.9 million, up from $411.7 million a year earlier, driven by net product revenues of $426.5 million, which were primarily attributed to higher sales volume and higher average net selling price. GAAP net income was $1.0 million, or $0.00 per share, compared with $73.2 million, or $0.23 per share, in the prior-year quarter, as research and development expenses rose to $332.6 million from $198.8 million and selling, general and administrative expenses rose to $138.1 million from $115.0 million. Non-GAAP net income, which excludes stock-based compensation, was $32.1 million, or $0.10 per share. The company updated its 2023 guidance, forecasting total revenues of $1.825 billion to $1.850 billion, net product revenues of $1.625 billion to $1.650 billion, research and development expenses of $1.050 billion to $1.075 billion, and selling, general and administrative expenses of $525 million to $550 million. On the clinical front, the CONTACT-02 trial of cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer met one of two primary endpoints, with overall survival data still immature, and the COSMIC-313 second interim overall survival analysis did not reach statistical significance, so that trial continues to a 2024 analysis. The CABINET phase 3 trial in neuroendocrine tumors showed statistically significant progression-free survival improvement and will be discussed with the FDA. Corporate developments include a settlement with Teva Pharmaceuticals that permits a generic version of CABOMETYX in the U.S. beginning January 1, 2031, if approved; the in-licensing of XL309 from Insilico Medicine for an $80 million upfront payment; the appointment of Amy Peterson, M.D., as Chief Medical Officer; and a share repurchase program authorizing up to $550 million of common stock before the end of 2023, under which 16.943 million shares had been repurchased for $344.8 million as of September 30, 2023.
Exelixis Quarterly Report for Q3 Ended Sep 29, 2023
Exelixis, Inc. reported third-quarter 2023 total revenues of $471.9 million, up from $411.7 million a year earlier, driven by net product revenues of $426.5 million (CABOMETYX $422.2 million). However, research and development expenses rose to $332.6 million from $198.8 million, largely due to an $80.0 million upfront payment to Insilico for the XL309 license and higher personnel and clinical trial costs. As a result, the company recorded income from operations of $(17.6) million, compared with $82.6 million a year earlier, and net income of $1.0 million, or $0.00 per diluted share, versus $73.2 million, or $0.23 per share, in the prior-year quarter. Interest income rose to $23.1 million from $9.5 million, reflecting higher interest rates. As of September 30, 2023, Exelixis held $1.9 billion in cash, cash equivalents and investments, compared with $2.1 billion at December 31, 2022, and management stated it expects current resources and revenues to fund operations for at least 12 months. During the first nine months of 2023 the company repurchased $344.8 million of common stock under a program authorized in March 2023 for up to $550 million, with approximately $205.2 million remaining available for repurchases before year-end 2023. Net cash provided by operating activities for the nine months was $322.8 million. The filing also highlights ongoing litigation over generic CABOMETYX. A settlement with Teva grants Teva a license to market a generic version in the U.S. beginning January 1, 2031, if approved by the FDA. The MSN II case is awaiting a judgment expected in the first half of 2024 following an October 2023 bench trial, and a Cipla ANDA case has been administratively closed. Pipeline updates include positive top-line results from the phase 3 CONTACT-02 trial in mCRPC, which met one of two primary endpoints, and a phase 3 COSMIC-313 interim overall survival analysis that did not reach statistical significance, with the trial continuing to its next analysis in 2024.
Exelixis 8-K Report, Executive Changes (Sep 19, 2023)
Exelixis, Inc. filed this Form 8-K to report that Vicki L. Goodman, M.D., concluded her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, effective August 23, 2023, as previously reported in an 8-K dated August 23, 2023. The filing describes her departure under a Separation Agreement and Release of All Claims entered into on September 13, 2023. Under that agreement, she will receive the severance payments and benefits she is entitled to under the Company's Change in Control and Severance Benefit Plan, paid in a lump sum and subject to the plan's conditions, including execution of a general release of claims. The Company and Dr. Goodman also entered into a Consulting Agreement under which she will serve as a consultant for a period not to exceed four months between September 1, 2023 and December 31, 2023, for a monthly fee of $20,000. Either party may terminate the consulting arrangement at any time on five business days' prior written notice. The filing states that the full text of the Separation Agreement and Consulting Agreement is expected to be filed as exhibits to the Company's Form 10-Q for the period ending September 29, 2023. For investors, the main takeaways are the leadership transition at the chief medical officer role and the defined transition terms, including the consulting fee and severance structure.
Exelixis 8-K Report, Executive Changes (Aug 23, 2023)
Exelixis, Inc. filed this Current Report on Form 8-K dated August 23, 2023, to disclose a leadership change under Item 5.02. Effective August 23, 2023, Vicki L. Goodman, M.D., concluded her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of the company. The filing states that, in connection with her departure, Dr. Goodman is entitled to payments under the company's Change in Control and Severance Benefit Plan, as amended and restated. No dollar amounts for these payments are stated in the filing. The filing is brief and does not disclose financial results, clinical data, guidance, or other operating developments. Its main investor relevance is the departure of a senior executive responsible for product development and medical affairs, a function that oversees the company's clinical and medical programs. The filing does not state a successor or interim arrangement for the role. The report was signed by Jeffrey J. Hessekiel, Executive Vice President, General Counsel and Secretary. Exelixis common stock, par value $.001 per share, trades under the symbol EXEL on The Nasdaq Stock Market LLC.
Exelixis 8-K Report, Financial Results (Aug 1, 2023)
Exelixis, Inc. (Nasdaq: EXEL) filed this Form 8-K under Item 2.02 to furnish its press release announcing financial results for the quarter ended June 30, 2023 and providing a corporate update. Total revenues were $469.8 million for the quarter, compared with $419.4 million a year earlier, driven by net product revenues of $409.6 million (up from $347.0 million), which the company attributes to higher sales volume and a higher average net selling price. Collaboration revenues declined to $60.2 million from $72.4 million, mainly due to lower milestone recognition and development cost reimbursements, partly offset by higher royalties. GAAP net income was $81.2 million, or $0.25 per diluted share, versus $70.7 million, or $0.22, a year earlier; non-GAAP net income, which excludes stock-based compensation, was $100.3 million, or $0.31 per diluted share. R&D expenses rose to $232.6 million and SG&A rose to $141.7 million, the latter including legal and advisory fees related to a recent proxy contest. Exelixis maintained its fiscal 2023 guidance, with total revenues of $1.775 billion to $1.875 billion, net product revenues of $1.575 billion to $1.675 billion, R&D expenses of $1,000 million to $1,050 million, and SG&A expenses of $475 million to $525 million. The release also reports a settlement of CABOMETYX patent litigation with Teva, under which Teva may market a generic version in the U.S. beginning January 1, 2031, if approved by the FDA. The company had repurchased $127.0 million of its common stock as of June 30, 2023, at an average price of $19.22 per share, under a board authorization of up to $550 million to be used before the end of 2023. Management also highlighted upcoming catalysts, including the readout of the phase 3 CONTACT-02 study, the next overall survival analysis from COSMIC-313, and an R&D Day planned for December 12, 2023.
Exelixis Quarterly Report for Q2 Ended Jun 30, 2023
Exelixis, Inc. reported financial results for the quarter ended June 30, 2023 in this Form 10-Q. Total revenues for the second quarter were $469.8 million, up from $419.4 million a year earlier, driven by net product revenues of $409.6 million (CABOMETYX $403.3 million). Income from operations was $77.8 million, and net income was $81.2 million, or $0.25 per share basic and diluted, compared with $70.7 million, or $0.22 per share, in the second quarter of 2022. Research and development expenses rose to $232.6 million and selling, general and administrative expenses rose to $141.7 million. For the six months ended June 30, 2023, total revenues were $878.6 million and net income was $121.2 million. The company ended the quarter with $2.1 billion in cash, cash equivalents and investments, and states it expects its resources to fund operations for at least 12 months. During the six months, Exelixis repurchased $127.0 million of common stock under a $550 million program authorized in March 2023, leaving approximately $423.0 million available. Operating cash flow for the six months was $205.4 million. The filing highlights legal and competitive risk around CABOMETYX. On July 18, 2023, the company entered into a settlement and license agreement with Teva that grants Teva a license to market a generic version in the U.S. beginning January 1, 2031, if approved by the FDA. Litigation against MSN and Cipla over generic ANDA filings remains ongoing, and the filing states that a generic launch could significantly decrease U.S. CABOMETYX revenues. The filing also notes that the Inflation Reduction Act and other drug pricing initiatives could affect future revenues.
Exelixis 8-K Report, Corporate Update (Jul 24, 2023)
Exelixis, Inc. reported in a Form 8-K filed July 24, 2023 under Item 8.01 (Other Events) that on July 23, 2023 it entered into a Settlement and License Agreement with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (collectively Teva). The agreement resolves patent litigation Exelixis brought over Teva's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of CABOMETYX (cabozantinib) tablets (20 mg, 40 mg and 60 mg) before the applicable patents expire. Under the terms, Exelixis will grant Teva a license to market its generic version of CABOMETYX in the United States beginning January 1, 2031, if approved by the U.S. Food and Drug Administration and subject to conditions and exceptions common to agreements of this type. The parties will also terminate all ongoing Hatch-Waxman Act litigation regarding CABOMETYX patents pending in the U.S. District Court for the District of Delaware. The filing states the Agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. For investors, the key takeaway is that generic competition to CABOMETYX in the United States is set to begin no earlier than January 1, 2031, resolving the Teva patent dispute without further litigation.
Exelixis 8-K Report, Shareholder Vote Results (Jun 5, 2023)
At its 2023 Annual Meeting of Stockholders, held May 31, 2023 at its Alameda, California offices, Exelixis, Inc. elected 11 directors to serve until the 2024 annual meeting. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 29, 2023, and approved, on an advisory basis, the compensation of the named executive officers (Say-on-Pay). The votes in favor of Say-on-Pay were 212,824,174, against were 42,820,366, and abstentions were 1,171,837. Stockholders also expressed a preference for holding advisory Say-on-Pay votes every year, with 250,754,219 votes for "1 Year" compared with 262,732 for "2 Years" and 5,363,172 for "3 Years." In response, the Board determined that future advisory votes on executive compensation will be held annually until the next such vote. The filing notes that Dr. Lance Willsey resigned from the Board, as previously disclosed on May 7, 2023, and did not stand for re-election. The reported vote totals therefore exclude any votes cast for him. The filing reports no other matters submitted for stockholder action.